Cite
HARVARD Citation
Demirhan, Y. et al. (n.d.). S318 Optimized Lower Dose Combinations of Sulindac Plus Erlotinib Sustained Antitumor Efficacy and Reduced Toxicity in a Preclinical Model of FAP. American journal of gastroenterology. p. S138. [Online].